Speaker Series - Continuing care of the mCRPC patient

This publication is a summary of presentations given by Associate Professor Nathan Lawrentschuk (Urological Surgeon and Oncologist, University of Melbourne, Austin Hospital and Olivia Newton-John Cancer Research Institute, and Peter MacCallum Cancer Institute) and Dr Venu Chalasani (Urological Surgeon, University of Sydney) at a workshop of the Urological Society of Australia and New Zealand held at the Gold Coast, Australia (16 April 2016).

The presentations focused primarily on the following topics: oligometastatic prostate cancer and its potential treatment; PET-CT and its applications in prostate cancer, with a focus on prostate-specific membrane antigen (PSMA) PET-CT; and systemic treatments for prostate cancer and their inclusion in the latest European Association of Urology (EAU) guidelines, focussing on metastatic prostate cancer (mPC) and the newer agents enzalutamide and abiraterone.

Please login below to download this issue (PDF)